Sarepta Therapeutics Announces Second Quarter 2017 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Sarepta Therapeutics (SRPT) PT Raised to $33 at Morgan Stanley
July 20, 2017 9:16 AM EDTMorgan Stanley raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $33.00 (from $31.00) while maintaining a Equalweight rating.
... MoreSarepta Therapeutics (SRPT) PT Raised to $69 at Cowen Following 'Beat and Raise'
July 20, 2017 6:07 AM EDTCowen analyst Ritu Baral raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $69.00 (from $62.00) while maintaining a Outperform rating following a solid beat and raise for Exondys 51 revenues.
Baral sees continued progress with both prescribers and payors... More
